KRAS and lung cancer: In support of this, higher levels of PROX1 were observed in KRAS-driven LKB1-mutant (KL), the upstream kinase for AMPK, lung tumours, compared with either lung cancer subtypes of KRAS (K) or concomitant KRAS and TP53 mutation (KP) from TCGA database (Fig. 1d).